alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › subjective-cognitive-decline

subjective-cognitive-decline

8 studies tagged subjective-cognitive-decline, dated 2015-02-25 to 2023-09-12. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Plasma p-tau181 as a promising non-invasive biomarker of Alzheimer's Disease pathology in Subjective Cognitive Decline and Mild Cognitive Impairment 2023-09-12
  2. Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive decline 2023-01-05
  3. Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status 2022-11-03

Studies

8 studies carry this tag.

Date range

2015 to 2023

Top journals

  • Alzheimer's research & therapy 4
  • Journal of neurology 1
  • Journal of the neurological sciences 1
  • Neurology 1
  • Scientific reports 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Plasma p-tau181 as a promising non-invasive biomarker of Alzheimer's Disease pathology in Subjective Cognitive Decline and Mild Cognitive Impairment

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of the neurological sciences 2023-09-12 Biomarkers

    Plasma p-tau181 levels were influenced by the presence of underlying AD pathology, independently from the cognitive status and were highly accurate in differentiating SCD-MCI patients who were carriers of AD pathology from non-carriers.

  2. Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive decline

    ✓ Peer-reviewed alzhub usefulness score 72 out of 100. Alzheimer's research & therapy 2023-01-05 Biomarkers

    This study suggests that plasma Aβ42/Aβ40, as determined by this MS-based assay, has potential value as an accurate and cost-effective tool to identify individuals in the earliest stages of AD, supporting its implementation in clinical trials, preventative strategies and clinical practice.

  3. Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Alzheimer's research & therapy 2022-11-03 Biomarkers

    Our findings indicate that the high plasma AβO level could serve as a potential surrogate biomarker of severe SCD and the presence of brain Aβ deposition in individuals with normal objective cognition.

  4. Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of neurology 2022-03-14 Biomarkers

    Plasma NfL levels might be a promising biomarker for neurodegeneration to discriminate cognitive decline due to AD from other conditions causing cognitive impairment in prodromal stages.

  5. Anxiety correlates with cortical surface area in subjective cognitive decline: APOE ε4 carriers versus APOE ε4 non-carriers

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer's research & therapy 2019-06-03 Biomarkers

    Individuals with SCD had an altered cortical surface area, and APOE genotype and anxiety symptoms are modified factors on the cortical surface area decrease in SCD.

  6. Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI)

    ✓ Peer-reviewed alzhub usefulness score 53 out of 100. Alzheimer's research & therapy 2018-11-29 Biomarkers

    To facilitate clinical trials of disease-modifying therapies, plasma concentrations of Aβ species are good candidates for peripheral AD biomarkers, but studies to date have generated conflicting results.

  7. Tau plasma levels in subjective cognitive decline: Results from the DELCODE study

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Scientific reports 2017-08-25 Biomarkers

    Previous studies have demonstrated increased tau plasma levels in patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI) due to AD.

  8. Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI

    ✓ Peer-reviewed alzhub usefulness score 56 out of 100. Neurology 2015-02-25 Biomarkers

    In MCI, specific aspects of SCD severity and quality are related to CSF biomarkers indicative of AD.

All topic tags with their study counts